路透9月2日 - Ultragenyx制药公司(RARE.O)周三表示,其用于治疗一种罕见遗传性神经发育障碍的试验性药物在后期临床试验中未达到主要目标。
路透9月2日 - Ultragenyx制药公司(RARE.O)周三表示,其用于治疗一种罕见遗传性神经发育障碍的试验性药物在后期临床试验中未达到主要目标。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.